Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 751–760 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 751
- Medicine slug
- indium-in-111-oxyquinoline
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
67.2 hours
- Numeric value
- 67.2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7dbfc0f9-0e2e-4aed-85bd-32cf7c74d402 (opens source in a new tab)
Indium In-111 Oxyquinoline label
Version not recorded · Effective date not recorded
Clearance from liver and spleen, for the purpose of calculating the radiation dose, is assumed to be equal to the physical half-life of indium In 111 (67.2 hours).
67.9 hours
- Numeric value
- 67.9
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c52c904-8137-4b10-8a85-d9b96c2d8a00 (opens source in a new tab)
Indium In-111 Oxyquinoline label
Version not recorded · Effective date not recorded
Clearance from liver and spleen, for the purpose of calculating the radiation dose, is assumed to be equal to the physical half-life of indium In 111 (67.9 hours).
Projected row 752
- Medicine slug
- indomethacin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 77
- Source count
- 77
- Agreement rate
- 0.961039
- Recorded readings
4.5 hours
- Numeric value
- 4.5
- Unit
- hours
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:503455d9-471e-554f-e054-00144ff88e88 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73878376-1d24-423b-9f37-3666e83c95da (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b48d2b3-61b5-4cfc-a8a0-7ccc235dfe5a (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:971c4d53-7876-4f42-ba2d-c391714fa341 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532d40b2-c05c-4d4f-b7ee-e6434c4c27fc (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ed39e2-5431-4e47-935c-c7441d058f94 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d35bafd6-076d-4b94-bb0f-99be0addb505 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8a572d-e0e1-4d37-b3c4-b85415d50393 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aa48212-19b0-4304-9c61-dcf4db2b19ea (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6126527-5272-4477-8716-d05365a05225 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f4a5796-5317-4caa-83e4-0595fe844df4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf93022c-a965-49c5-a852-c59e580d7d91 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2997707-1541-4f5d-8c8d-70b0a13be8b2 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efa111d5-ade4-4944-97e4-3c37b8b14ea8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c81343f2-5ef5-4635-9b94-5ac8d72aa61e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d9a253a-f014-4fab-e054-00144ff8d46c (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56e19868-3973-4f1b-b80f-1f7daf1f1c22 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2033059b-4be1-42d0-b888-34d8202f3e09 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc80228c-acae-44dc-9762-19bd1669bf45 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12f62bae-5fc0-4f8d-a8b4-446524bd53d1 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85014b51-1354-4d16-9995-3ee33a7155fa (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a65b650-ea9b-4d0d-b62f-5971df1e62b4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3d4fbff-d9d5-4dbb-bf01-ca2efc3bcf30 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66e3205b-eab1-4864-bf36-116e9d79fe3e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e8796a6-94c6-0db2-e054-00144ff88e88 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9236d783-d7b8-4486-94c6-5ecd876bc475 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4e8a719-ef9c-a2ef-e053-2995a90ad788 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54d6e12-e827-4248-819a-de76afa70371 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9607920c-4d25-40b9-957e-87e9ca5574e8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8b86758-6cb5-44ac-a5fc-2111e98a19a8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:009097a5-2c1e-4f5d-8054-896cf896cb3d (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d66ada00-3ece-4b71-8c59-a0db48a2db80 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12821a3a-b5f2-4415-84c9-0a30a4725f1e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e7175d7-5e43-4151-9702-88ac2cd44ef6 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a329976b-4a01-42ea-a666-0ac99ed2522e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67b16cf2-e24c-4fe3-8d74-e63549b7659f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbad7e61-2347-43b1-a422-9183e41c10ea (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fd56b7d-2799-4211-9a58-c6c1dc8c70dc (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b05b8bc-4df0-4175-bf53-72129fb21b50 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4cf01d1-0d71-4f0f-97a5-07a59744149f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:175a2d81-0d0f-46a3-aaaa-1732982d85fd (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afbb24fd-3695-4a30-a8a6-36239e35a14f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac458b4b-95bb-4235-a447-e8c4ba720257 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f4eda2-5c8f-72eb-e053-2a95a90a06be (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db0f1127-ebd8-636c-e053-2a95a90a4d44 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6312c9a6-d4d3-eb1f-e053-2991aa0a5e68 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99d7a84b-c755-47be-9d2d-1223162b0a42 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595e2f3e-c6d4-4a17-bc06-46512b4275b5 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfdcdb27-07a0-47e6-b8da-d9c99045a066 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86c94559-b453-4e61-a76c-6962872f0655 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e87e34a-6556-4b0f-e054-00144ff8d46c (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc7ef3b-fddd-49dd-85d1-cbb3d5c17ff7 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bb30cef-c460-4696-8acd-a453408640f4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:927af761-2f37-4e81-a86e-d4fb17cc1897 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3785c914-0037-49ef-b6f5-a5e868ae490b (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51266787-b50e-bc15-e063-6394a90ad16f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf11f5a0-f2ee-499a-8d54-9d557cc66841 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d9ef14a-4812-4fcf-e054-00144ff8d46c (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce866d3a-7bea-4d82-9b7d-79e8a294c141 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205fc4e7-e118-509e-e063-6394a90a78e6 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41af7776-36bc-4820-b635-e7c69f26997e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c15102c-b6f9-4198-b592-152160591014 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ce37860-407f-47c7-a64c-62b6cc729298 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c911ac4-db70-44bf-8374-01c8260aa3d4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b36645c-de5e-4263-ae06-2f6ff6a9add2 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb80a9f-def3-4228-ab04-a0c2a117a2b9 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ce9c3c5-0cf7-4760-988d-2559adcfb200 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16238287-d4b0-4afa-8483-1f4ae250a625 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f59f63-fcda-2a80-e053-2995a90ab087 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b094eb04-3177-431d-b5ac-edc4804750a2 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcaa0e51-a2fc-cf74-027a-1964e38c5e4e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1bb9349-21e4-4e6a-9916-3aac6c4d01b8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7755391e-ede3-4a32-854c-736dc6dd2ee3 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dffe9b95-3cb6-4c4e-e053-2a95a90a9328 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
The mean half-life of indomethacin is estimated to be about 4.5 hours.
20 hours
- Numeric value
- 20
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd5caa3f-3c09-4034-bf43-2df80c61c07b (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
In one study, of 28 neonates who could be evaluated, the plasma half-life in those less than 7 days old averaged 20 hours (range: 3 to 60 hours, n=18).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30e38747-c553-4e2d-bc23-634e1dd90b8d (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
In one study, of 28 neonates who could be evaluated, the plasma half-life in those less than 7 days old averaged 20 hours (range: 3 to 60 hours, n=18).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec482425-358c-4500-8f5d-79c1379c1fa8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
In one study, of 28 neonates who could be evaluated, the plasma half-life in those less than 7 days old averaged 20 hours (range: 3 to 60 hours, n=18).
Projected row 753
- Medicine slug
- indomethacin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 77
- Source count
- 68
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 68
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 68 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:503455d9-471e-554f-e054-00144ff88e88 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73878376-1d24-423b-9f37-3666e83c95da (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of INDOCIN Capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b48d2b3-61b5-4cfc-a8a0-7ccc235dfe5a (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:971c4d53-7876-4f42-ba2d-c391714fa341 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532d40b2-c05c-4d4f-b7ee-e6434c4c27fc (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ed39e2-5431-4e47-935c-c7441d058f94 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d35bafd6-076d-4b94-bb0f-99be0addb505 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. 12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc8a572d-e0e1-4d37-b3c4-b85415d50393 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aa48212-19b0-4304-9c61-dcf4db2b19ea (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f4a5796-5317-4caa-83e4-0595fe844df4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf93022c-a965-49c5-a852-c59e580d7d91 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d2997707-1541-4f5d-8c8d-70b0a13be8b2 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c81343f2-5ef5-4635-9b94-5ac8d72aa61e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d9a253a-f014-4fab-e054-00144ff8d46c (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56e19868-3973-4f1b-b80f-1f7daf1f1c22 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2033059b-4be1-42d0-b888-34d8202f3e09 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of Indomethacin Capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc80228c-acae-44dc-9762-19bd1669bf45 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12f62bae-5fc0-4f8d-a8b4-446524bd53d1 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85014b51-1354-4d16-9995-3ee33a7155fa (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a65b650-ea9b-4d0d-b62f-5971df1e62b4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3d4fbff-d9d5-4dbb-bf01-ca2efc3bcf30 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66e3205b-eab1-4864-bf36-116e9d79fe3e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e8796a6-94c6-0db2-e054-00144ff88e88 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9236d783-d7b8-4486-94c6-5ecd876bc475 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9607920c-4d25-40b9-957e-87e9ca5574e8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8b86758-6cb5-44ac-a5fc-2111e98a19a8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of INDOCIN Capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:009097a5-2c1e-4f5d-8054-896cf896cb3d (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d66ada00-3ece-4b71-8c59-a0db48a2db80 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12821a3a-b5f2-4415-84c9-0a30a4725f1e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e7175d7-5e43-4151-9702-88ac2cd44ef6 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a329976b-4a01-42ea-a666-0ac99ed2522e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67b16cf2-e24c-4fe3-8d74-e63549b7659f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbad7e61-2347-43b1-a422-9183e41c10ea (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fd56b7d-2799-4211-9a58-c6c1dc8c70dc (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b05b8bc-4df0-4175-bf53-72129fb21b50 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4cf01d1-0d71-4f0f-97a5-07a59744149f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:175a2d81-0d0f-46a3-aaaa-1732982d85fd (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afbb24fd-3695-4a30-a8a6-36239e35a14f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f4eda2-5c8f-72eb-e053-2a95a90a06be (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db0f1127-ebd8-636c-e053-2a95a90a4d44 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6312c9a6-d4d3-eb1f-e053-2991aa0a5e68 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99d7a84b-c755-47be-9d2d-1223162b0a42 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595e2f3e-c6d4-4a17-bc06-46512b4275b5 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of Indomethacin Capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 mcg/mL and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86c94559-b453-4e61-a76c-6962872f0655 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e87e34a-6556-4b0f-e054-00144ff8d46c (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cc7ef3b-fddd-49dd-85d1-cbb3d5c17ff7 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bb30cef-c460-4696-8acd-a453408640f4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:927af761-2f37-4e81-a86e-d4fb17cc1897 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3785c914-0037-49ef-b6f5-a5e868ae490b (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51266787-b50e-bc15-e063-6394a90ad16f (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf11f5a0-f2ee-499a-8d54-9d557cc66841 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d9ef14a-4812-4fcf-e054-00144ff8d46c (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce866d3a-7bea-4d82-9b7d-79e8a294c141 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205fc4e7-e118-509e-e063-6394a90a78e6 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41af7776-36bc-4820-b635-e7c69f26997e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c15102c-b6f9-4198-b592-152160591014 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ce37860-407f-47c7-a64c-62b6cc729298 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c911ac4-db70-44bf-8374-01c8260aa3d4 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of Indomethacin Capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 mcg/mL and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b36645c-de5e-4263-ae06-2f6ff6a9add2 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb80a9f-def3-4228-ab04-a0c2a117a2b9 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ce9c3c5-0cf7-4760-988d-2559adcfb200 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16238287-d4b0-4afa-8483-1f4ae250a625 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f59f63-fcda-2a80-e053-2995a90ab087 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin immediate-release capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b094eb04-3177-431d-b5ac-edc4804750a2 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcaa0e51-a2fc-cf74-027a-1964e38c5e4e (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. 12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1bb9349-21e4-4e6a-9916-3aac6c4d01b8 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7755391e-ede3-4a32-854c-736dc6dd2ee3 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules, 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dffe9b95-3cb6-4c4e-e053-2a95a90a9328 (opens source in a new tab)
Indomethacin label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours.
Projected row 754
- Medicine slug
- infliximab
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
7.7 to 9.5 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0a046c1-056d-45a9-bfd9-13b47c24f257 (opens source in a new tab)
Infliximab label
Version not recorded · Effective date not recorded
Pharmacokinetic results for single doses of 3 mg/kg to 10 mg/kg in RA, 5 mg/kg in CD, and 3 mg/kg to 5 mg/kg in Ps indicate that the median terminal half-life of infliximab is 7.7 to 9.5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b05c174f-832c-4321-b34f-2c4ad3742269 (opens source in a new tab)
Infliximab label
Version not recorded · Effective date not recorded
Pharmacokinetic results for single doses of 3 mg/kg to 10 mg/kg in RA, 5 mg/kg in CD, and 3 mg/kg to 5 mg/kg in Ps indicate that the median terminal half-life of infliximab is 7.7 to 9.5 days.
Projected row 755
- Medicine slug
- infliximab-dyyb
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
332 hours
- Numeric value
- 332
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93a193ab-9f96-4da6-aa7c-31212e81879a (opens source in a new tab)
Infliximab-Dyyb label
Version not recorded · Effective date not recorded
Elimination In healthy subjects, the mean half-life was 332 hours after a single subcutaneous dose of infliximab-dyyb 120 mg.
7.7 to 9.5 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37eaca10-d812-48bc-8b8e-b836bfa9968f (opens source in a new tab)
Infliximab-Dyyb label
Version not recorded · Effective date not recorded
Pharmacokinetic results for single doses of 3 mg/kg to 10 mg/kg in RA, 5 mg/kg in CD, and 3 mg/kg to 5 mg/kg in Ps indicate that the median terminal half-life of infliximab is 7.7 to 9.5 days.
Projected row 756
- Medicine slug
- insulin-aspart
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 13
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
30%
- Numeric value
- 30
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19888a44-b330-462a-864d-338c5893dd63 (opens source in a new tab)
Insulin Aspart label
Version not recorded · Effective date not recorded
Absorption and Bioavailability The 30% insulin aspart in the soluble component of NOVOLOG MIX 70/30 is absorbed rapidly from the subcutaneous layer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1861fcee-7673-4afe-a206-08fa05c0add2 (opens source in a new tab)
Insulin Aspart label
Version not recorded · Effective date not recorded
Absorption and Bioavailability The 30% insulin aspart in the soluble component of NOVOLOG MIX 70/30 is absorbed rapidly from the subcutaneous layer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d9f0e10-edb9-4960-bd62-cf406e75bbe7 (opens source in a new tab)
Insulin Aspart label
Version not recorded · Effective date not recorded
Absorption and Bioavailability The 30% insulin aspart in the soluble component of Insulin Aspart Protamine and Insulin Aspart is absorbed rapidly from the subcutaneous layer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66da64f7-ca50-47d2-95fa-de37005eef85 (opens source in a new tab)
Insulin Aspart label
Version not recorded · Effective date not recorded
Absorption and Bioavailability The 30% insulin aspart in the soluble component of NOVOLOG MIX 70/30 is absorbed rapidly from the subcutaneous layer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc94baa4-3606-48bc-a781-9617ab6960ef (opens source in a new tab)
Insulin Aspart label
Version not recorded · Effective date not recorded
Absorption and Bioavailability The 30% insulin aspart in the soluble component of Insulin Aspart Protamine and Insulin Aspart is absorbed rapidly from the subcutaneous layer.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14499781-b90e-47d5-a7de-006965439b94 (opens source in a new tab)
Insulin Aspart label
Version not recorded · Effective date not recorded
Absorption and Bioavailability The 30% insulin aspart in the soluble component of Insulin Aspart Protamine and Insulin Aspart is absorbed rapidly from the subcutaneous layer.
Projected row 757
- Medicine slug
- insulin-degludec
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
25 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8ccd2f4-6ba9-4839-87f8-4742dc9b1c17 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
On average, the half-life at steady state is approximately 25 hours independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84197351-cb71-4282-8217-13103404a2b4 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
On average, the half-life at steady state is approximately 25 hours independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62128c8b-f613-44d9-af04-18d52c4348cd (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
On average, the half-life at steady state is approximately 25 hours independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a4bd8e5-7af4-4573-97c2-9945faf6a7dd (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
On average, the half-life at steady state is approximately 25 hours independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1be283d-4b1d-4996-b2a7-4488dbff3037 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
On average, the half-life at steady state is approximately 25 hours independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:456c5e87-3dfd-46fa-8ac0-c6128d4c97c6 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
On average, the half-life at steady state is approximately 25 hours independent of dose.
Projected row 758
- Medicine slug
- insulin-degludec
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
>99%
- Numeric value
- 99
- Unit
- %
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8ccd2f4-6ba9-4839-87f8-4742dc9b1c17 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
Distribution The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of >99% in human plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84197351-cb71-4282-8217-13103404a2b4 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
Distribution The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of >99% in human plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62128c8b-f613-44d9-af04-18d52c4348cd (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
Distribution The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of >99% in human plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a4bd8e5-7af4-4573-97c2-9945faf6a7dd (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
Distribution The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of >99% in human plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1be283d-4b1d-4996-b2a7-4488dbff3037 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
Distribution The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of >99% in human plasma.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:456c5e87-3dfd-46fa-8ac0-c6128d4c97c6 (opens source in a new tab)
Insulin Degludec label
Version not recorded · Effective date not recorded
Distribution The affinity of insulin degludec to serum albumin corresponds to a plasma protein binding of >99% in human plasma.
Projected row 759
- Medicine slug
- insulin-detemir
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38d65c1-25bf-401d-9c7e-a2c3222da8af (opens source in a new tab)
Insulin Detemir label
Version not recorded · Effective date not recorded
The absolute bioavailability of insulin detemir is approximately 60%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82192527-99aa-4b53-8ce9-9173668d309c (opens source in a new tab)
Insulin Detemir label
Version not recorded · Effective date not recorded
The absolute bioavailability of insulin detemir is approximately 60%.
Projected row 760
- Medicine slug
- insulin-detemir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
5 to 7 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38d65c1-25bf-401d-9c7e-a2c3222da8af (opens source in a new tab)
Insulin Detemir label
Version not recorded · Effective date not recorded
Elimination After subcutaneous administration in patients with type 1 diabetes, insulin detemir has a terminal half-life of 5 to 7 hours depending on dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82192527-99aa-4b53-8ce9-9173668d309c (opens source in a new tab)
Insulin Detemir label
Version not recorded · Effective date not recorded
Elimination After subcutaneous administration in patients with type 1 diabetes, insulin detemir has a terminal half-life of 5 to 7 hours depending on dose.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=750Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.